摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-6-甲基哒嗪 | 65202-58-6

中文名称
3-溴-6-甲基哒嗪
中文别名
3-溴-6-甲基吡嗪
英文名称
6-methyl-3-bromopyridazine
英文别名
3-bromo-6-methylpyridazine;3-bromo-6-methyl-pyridazine;3-Brom-6-methyl-pyridazin;6-Methyl-3-brom-pyridazin
3-溴-6-甲基哒嗪化学式
CAS
65202-58-6
化学式
C5H5BrN2
mdl
——
分子量
173.012
InChiKey
RACIHBXDZONTQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    285.0±20.0 °C(Predicted)
  • 密度:
    1.596±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:081c84861e1c53d876cb023dc70124e0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Bromo-6-methylpyridazine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-6-methylpyridazine
CAS number: 65202-58-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5BrN2
Molecular weight: 173.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PARG INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE PARG
    申请人:CANCER REC TECH LTD
    公开号:WO2016097749A1
    公开(公告)日:2016-06-23
    The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.
    本发明涉及作为PARG(Poly ADP-ribose glycohydrolase)酶活性抑制剂的化合物I的公式,其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c分别如本文所定义。本发明还涉及制备这些化合物的方法,包括含有它们的药物组合物,以及它们在治疗增殖性疾病(如癌症)以及其他涉及PARG活性的疾病或症状中的用途。
  • Pyrrolidine modulators of chemokine receptor activity
    申请人:Merck & Co., Inc.
    公开号:US06265434B1
    公开(公告)日:2001-07-24
    The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
    本发明涉及式1的吡咯烷化合物:(其中R1、R2、R3、R4、R5、R6和n在此处定义),这些化合物可用作趋化因子受体活性的调节剂。具体来说,这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
  • [EN] C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY<br/>[FR] TRITERPÉNOÏDES MODIFIÉS EN C-17 ET C-3 PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE LA MATURATION DU VIH
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2012106190A1
    公开(公告)日:2012-08-09
    Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III. These compounds are useful for the treatment of HIV and AIDS.
    具有药物和生物影响特性的化合物,其药物组合物和使用方法已列出。具体来说,提供了具有独特抗病毒活性的C-17和C-3修饰三萜类化合物,作为HIV成熟抑制剂,如公式I、II和III所代表的化合物。这些化合物对治疗HIV和艾滋病有用。
  • [EN] NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM<br/>[FR] NOUVEAUX DÉRIVÉS TRIAZOLYLES UTILISÉS EN TANT QUE GABA A ALPHA5 PAM
    申请人:HOFFMANN LA ROCHE
    公开号:WO2021228795A1
    公开(公告)日:2021-11-18
    The invention provides novel compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    本发明提供了具有通用公式(I)或(II)的新颖化合物,其中R1、R2、R3、X、Y和Z如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。
  • [EN] ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS ÉTHER POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
    申请人:ACHILLION PHARMACEUTICALS INC
    公开号:WO2017035355A1
    公开(公告)日:2017-03-02
    Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    提供了一种包括化合物、使用方法和制备过程的抑制补体因子D的方法,其中所述方法包括化合物I的结构,或其药用盐或组合物,其中A组上的R12或R13是醚取代基(R32)。本文描述的抑制剂靶向因子D并抑制或调节补体级联反应。本文描述的因子D抑制剂减少了补体的过度激活。
查看更多